Core Insights - Southbound funds increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 2.7215 million shares on October 17, 2025, marking a net increase of 21.9745 million shares over the last five trading days [1] - Over the past 20 trading days, Jinxin Reproductive Medicine has seen a total net increase of 62.8275 million shares from southbound funds, with 15 days of net buying activity [1] - As of now, southbound funds hold 1.441 billion shares of Jinxin Reproductive Medicine, accounting for 52.25% of the company's total issued ordinary shares [1] Summary by Category Trading Activity - On October 17, 2025, total shares held reached 1.441 billion, with a change of 2.7215 million shares, reflecting a 0.19% increase [2] - On October 16, 2025, total shares held were 1.439 billion, with a change of 3.8335 million shares, reflecting a 0.27% increase [2] - On October 15, 2025, total shares held were 1.435 billion, with a change of 11.2305 million shares, reflecting a 0.79% increase [2] - On October 14, 2025, total shares held were 1.424 billion, with a change of 5.1255 million shares, reflecting a 0.36% increase [2] - On October 13, 2025, total shares held were 1.418 billion, with a change of -93650 shares, reflecting a -0.07% decrease [2] Company Overview - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and maternal and pediatric medical services [2] - Jinxin Reproductive Medicine operates mainly in China and the United States [2]
锦欣生殖（01951.HK）：10月17日南向资金增持272.15万股